Recruiting
Phase 1

BBT001

Sponsor:

Bambusa Therapeutics

Code:

NCT06808477

Conditions

Atopic Dermatitis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Interventions

BBT001

Placebo

Study Details

Brief summary:

This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Conditions

Atopic Dermatitis

Study ID

NCT06808477

Start date

Feb 27, 2025

Status verified date

Jul, 2026

Completion date

Feb 28, 2027

Anticipated

Primary completion date

Feb 28, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Accepted

Key Inclusion Criteria

1. Negative pregnancy tests for women of childbearing potential.
2. Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
3. Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
4. Adequate contraception use (for men and women of childbearing potential).

Key Inclusion Criteria (Parts A, B, and D)

1. Age of 18-65 years.
2. Body mass index of 18 to 32 kg/m², weight capped at 120 kg.
3. No clinically significant abnormalities or history of relevant diseases.

Key Inclusion Criteria (Parts C and E only)

1. Age of 18-72 years.
2. Body mass index ≥16 kg/m², weight capped at 125 kg.
3. Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
4. Moderate to severe atopic dermatitis
5. Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
6. Atopic lesions cover ≥10% of body surface area (BSA)
7. Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.

Key Exclusion Criteria

1. Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
2. History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
3. Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
4. Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
5. Abnormal Electrocardiogram (ECG) findings
6. History of drug/alcohol abuse in the past 2 years.
7. Donated >500mL blood within 2 months of screening.
8. History of severe allergic reactions or hypersensitivity.

Key Exclusion Criteria (Parts A, B, and D only)

1\. History of atopic dermatitis

Key Exclusion Criteria (Parts C and E only)

1. Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
2. Receipt of immunoglobulin or blood products within 30 days.
3. Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
4. Chronic pruritus from conditions other than atopic dermatitis.
5. Acute/treated infections or chronic skin infections.
6. Current use of sedating antihistamines or corticosteroids.

Study Design

Enrollment

237 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Part A Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

experimental: Part B Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in healthy volunteers.

experimental: Part C Multiple Ascending Dose BBT001

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

placebo comparator: Part A Single Ascending Dose Placebo

A single dose of Placebo will be administered in healthy volunteers

placebo comparator: Part B Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in healthy volunteers.

placebo comparator: Part C Multiple Ascending Dose Placebo

Multiple doses of Placebo will be administered in patients with atopic dermatitis.

active comparator: Part D Single Ascending Dose BBT001

A single dose of BBT001 will be administered in healthy volunteers

placebo comparator: Part D Single Ascending Dose Placebo

A single dose of placebo will be administered in healthy volunteers

active comparator: Part E Multiple Ascending Dose BBT001 - Dose Level 1

Multiple doses of BBT001 will be administered in patients with atopic dermatitis.

placebo comparator: Part E Multiple Ascending Dose Placebo

Multiple doses of placebo will be administered in patients with atopic dermatitis.

active comparator: Part E Multiple Ascending Dose BBT001 - Dose Level 2

Multiple doses of BBT001 will be administered in patients with atopic dermatitis

Interventions

BBT001

BBT001 will be administered

Placebo

Placebo will be administered

Primary outcome measure

  • Number of participants with adverse events following single and multiple administration of BBT001 [ Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration ]
  • Number of participants with change in serum blood parameters [ Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration ]
  • Number of participants with change in vital sign measurements following treatment administration. [ Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration ]
  • Number of participants with change in physical examination following treatment administration. [ Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration ]
  • Number of participants with change in 12-lead ECG readings [ Time Frame: Parts A and D - Up to Day 141; Parts B, C, and E - Up to Day 169 post first dose administration ]

Central Contacts and Locations

Locations

First OC Dermatology

Recruiting

Irvine, California, United States, 92614

OptiSkin Medical

Recruiting

New York, New York, United States, 10128

Equity Medical, LLC

Recruiting

The Bronx, New York, United States, 10455

More Information

Sponsor

Bambusa Therapeutics

Last update posted

Aug 13, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Bambusa Therapeutics on 2026-08-13.